Two Sigma Advisers
AKBA icon

Two Sigma Advisers’s Akebia Therapeutics AKBA Stock Holding History

Two Sigma Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-399,949
Closed -$644K – 70
2025
Q4 		$644K Buy
399,949
+272,100
+213% +$570K ﹤0.01% 1682
2025
Q3 		$349K Buy
127,849
+4,800
+4% +$16K ﹤0.01% 1910
2025
Q2 		$448K Sell
123,049
-6,700
-5% -$18.4K ﹤0.01% 1797
2025
Q1 		$249K Sell
129,749
-13,400
-9% -$27.4K ﹤0.01% 2056
2024
Q4 		$272K Sell
143,149
-44,700
-24% -$77.6K ﹤0.01% 2019
2024
Q3 		$248K Buy
187,849
+36,000
+24% +$48.1K ﹤0.01% 1991
2024
Q2 		$155K Sell
151,849
-8,100
-5% -$10K ﹤0.01% 2261
2024
Q1 		$293K Sell
159,949
-7,000
-4% -$11.2K ﹤0.01% 2075
2023
Q4 		$207K Sell
166,949
-6,500
-4% -$6.63K ﹤0.01% 2221
2023
Q3 		$198K Buy
173,449
+3,100
+2% +$3.98K ﹤0.01% 2100
2023
Q2 		$156K Sell
170,349
-48,000
-22% -$46.3K ﹤0.01% 2136
2023
Q1 		$122K Buy
218,349
+1,200
+0.6% +$917 ﹤0.01% 2352
2022
Q4 		$125K Buy
217,149
+1,200
+0.6% +$376 ﹤0.01% 2269
2022
Q3 		$68K Sell
215,949
-25,400
-11% -$9.97K ﹤0.01% 2351
2022
Q2 		$85K Sell
241,349
-98,100
-29% -$41.2K ﹤0.01% 2407
2022
Q1 		$244K Sell
339,449
-61,200
-15% -$131K ﹤0.01% 2313
2021
Q4 		$905K Buy
400,649
+37,757
+10% +$103K ﹤0.01% 1607
2021
Q3 		$1.04M Buy
362,892
+3,500
+1% +$9.99K ﹤0.01% 1600
2021
Q2 		$1.36M Sell
359,392
-609,753
-63% -$2.05M ﹤0.01% 1495
2021
Q1 		$3.28M Buy
969,145
+614,617
+173% +$2.21M 0.01% 1040
2020
Q4 		$993K Sell
354,528
-36,068
-9% -$105K ﹤0.01% 1572
2020
Q3 		$980K Buy
390,596
+197,995
+103% +$1.74M ﹤0.01% 1507
2020
Q2 		$2.62M Buy
192,601
+164,995
+598% +$1.71M 0.01% 1070
2020
Q1 		$209K Buy
+27,606
New +$215K ﹤0.01% 2153
2018
Q3 		– Sell
-48,400
Closed -$483K – 2213
2018
Q2 		$483K Sell
48,400
-34,300
-41% -$343K ﹤0.01% 1935
2018
Q1 		$788K Sell
82,700
-1,600
-2% -$22.4K ﹤0.01% 1645
2017
Q4 		$1.25M Buy
84,300
+5,800
+7% +$96.2K ﹤0.01% 1436
2017
Q3 		$1.54M Buy
78,500
+52,200
+198% +$803K ﹤0.01% 1334
2017
Q2 		$378K Buy
+26,300
New +$333K ﹤0.01% 1887

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Advisers's AKBA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 399,949 shares — an estimated $644K sold.

Two Sigma Advisers first reported a position in AKBA in Q2 2017 and held it in 29 quarters. The position peaked at $3.28M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 399,949 Akebia Therapeutics shares in Q1 2026, an estimated $644K.
  • Two Sigma Advisers first reported a position in Akebia Therapeutics in Q2 2017 and held it in 29 quarters.
  • Two Sigma Advisers's Akebia Therapeutics position peaked at $3.28M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.